Trial Profile
Phase I/II Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2636771 (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Cancer; Endometrial cancer; Malignant melanoma; Prostate cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Jul 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 31 Jul 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.
- 02 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.